Concepedia

Phase II Trial of Saracatinib (AZD0530), an Oral SRC-inhibitor for the Treatment of Patients with Hormone Receptor-negative Metastatic Breast Cancer

Ayca Gucalp, Joseph A. Sparano, James F. Caravelli, Jean T. Santamauro, Sujata Patil, A. Abbruzzi, Christine Pellegrino, J. Bromberg, Chau T. Dang, Maria Theodoulou,

Clinical Breast Cancer · 2011 · 159 citations · 27 references

DOIFull text

Open access

Concepts

References

27

Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer

Massimo Cristofanilli, G. Thomas Budd, Matthew J. Ellis et al. · New England Journal of Medicine · 2004 · 4.6K citations · Full text

, , +16

Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

Moshe Talpaz, Neil P. Shah, Hagop M. Kantarjian et al. · New England Journal of Medicine · 2006 · 1.8K citations · Full text

, , +15

Latent Bone Metastasis in Breast Cancer Tied to Src-Dependent Survival Signals

Xiang H.-F. Zhang, Qiongqing Wang, William L. Gerald et al. · Cancer Cell · 2009 · 658 citations · Full text

, , +16

Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia

Neil P. Shah, Hagop M. Kantarjian, Dong‐Wook Kim et al. · Journal of Clinical Oncology · 2008 · 488 citations · Full text

, , +15

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro

Richard S. Finn, Judy Dering, Charles Ginther et al. · Breast Cancer Research and Treatment · 2007 · 403 citations · Full text

, , +17